Clinical trials: Hepatitis C
Hepatitis C Virus Infection
Efficacy and Safety of Ledipasvir/Sofosbuvir, With or Without Ribavirin, in HCV Infected Participants Who Have Failed Prior Treatment With Sofosbuvir-based Therapies
The primary objective of this study is to evaluate the efficacy, safety, and tolerability of ledipasvir/sofosbuvir (LDV/SOF) fixed dose combination (FDC) for 12 weeks with or without ribavirin (RBV) in participants without…
- Trial name
- NCT02600351
- Testing
- LDV/SOF, RBV
- Where
- 42 sites in United States, Canada and 1 more
- Volunteers
- 87 people
- Sponsor
- Gilead Sciences
Hepatitis C, Chronic, Nonadherence, Patient
Digimeds to Optimize Adherence in Patients With Hepatitis C and Increased Risk for Nonadherence
This study evaluates the ability of digital medicines, Proteus Discover, to promote adherence and thus achieving a cure for hepatitis C in patients at high risk for not adhering to their hepatitis therapy.
- Trial name
- DASH (NCT03164902)
- Testing
- Digital Medicine
- Where
- 16 sites in United States
- Volunteers
- 253 people
- Sponsor
- Proteus Digital Health, Inc.
Asymptomatic Chronic HCV Carriers
Hyperimmune Bovine Colostrum - TRAVELAN™ for Patients With Chronic Hepatitis C Virus Infection Not Responding to Standard Therapy
This is an exploratory trial of Bovine Colostrum powder to decrease translocation of gut-derived microbial products and immune activation in HCV infection.
- Trial name
- NCT00956722
- Testing
- Bovine Colostrum Powder
- Where
- Israel
- Sponsor
- Hadassah Medical Organization
Hepatitis C, Chronic
Treatment of Chronic Hepatitis C With Pegylated Interferon and Ribavirin in Participants With/Without Substitution Therapy (P05255)
Although injection drug users represent the majority of new and existing cases of infection with hepatitis C virus (HCV), many lack access to treatment because of concerns about adherence, effectiveness, and reinfection.
- Trial name
- NCT00725751
- Testing
- Pegylated interferon alfa-2b (PegIFN-2b), Ribavirin
- Volunteers
- 353 people
- Sponsor
- Merck Sharp & Dohme LLC
Hepatitis C, Chronic
Efficacy and Safety of Peg-Interferon Alpha-2a Plus Ribavirin in Genotype 1 Chronic Hepatitis C Participants Co-Infected With Human Immunodeficiency Virus
This randomized, multi-center, Phase IV, comparative study will assess the efficacy and safety of combined peg-interferon alpha-2a (Peg-IFN-Alpha-2A) and ribavirin therapy for 48 or 72 weeks of treatment and 24 weeks of follow-up…
- Trial name
- NCT02761629
- Testing
- Peg-Interferon Alpha-2A, Ribavirin
- Where
- 17 sites in Brazil
- Volunteers
- 180 people
- Sponsor
- Hoffmann-La Roche
Chronic HCV Infection
Phase 2 Study of Yimitasvir Phosphate Capsules
The safety, tolerability and antiviral activity of DAG181/SOF in treatment-naive and treatment-experienced patients with chronic hepatitis C virus (HCV) genotype 1 infection
- Trial name
- NCT03458481
- Testing
- SOF, DAG181
- Where
- 17 sites in China
- Volunteers
- 129 people
- Sponsor
- Sunshine Lake Pharma Co., Ltd.
Chronic Hepatitis C Virus (HCV) Infection
A Study to Evaluate the Efficacy and Safety of ABT-493/ABT-530 in Renally Impaired Adults With Chronic Hepatitis C Virus Genotype 1 - 6 Infection
The purpose of this study is to assess the efficacy and safety of 12 weeks of treatment with the ABT-493/ABT-530 combination regimen in adults with chronic HCV genotype 1 - 6 infection and chronic severe renal impairment.
- Trial name
- EXPEDITION-4 (NCT02651194)
- Testing
- ABT-493/ABT-530
- Volunteers
- 104 people
- Sponsor
- AbbVie
HCV Infection
Study to Evaluate Effect of Sofosbuvir/Velpatasvir/GS-9857 Fixed-Dose Combination on the Pharmacokinetics of a Representative Hormonal Contraceptive Medication, Norgestimate/Ethinyl Estradiol
This study will evaluate the effect of sofosbuvir (SOF)/velpatasvir (VEL)/voxilaprevir (VOX) fixed-dose combination (FDC) + voxilaprevir on the pharmacokinetics (PK) of a representative hormonal contraceptive medication…
- Trial name
- NCT02533427
- Testing
- SOF/VEL/VOX, VOX, Norgestimate/ethinyl estradiol
- Where
- New Zealand
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- Gilead Sciences
Hepatitis C
Identification to Elimination in HCV-Infected Individuals
Approximately 3.5 - 5 million Americans are living with hepatitis C virus (HCV) in the United States. HCV significantly impacts rural Pennsylvania. It is estimated that 160,000 adults in Pennsylvania are living with hepatitis C.
- Trial name
- NCT03195205
- Testing
- OraQuick HCV Rapid Antibody Test
- Where
- United States
- Volunteers
- 3,051 people, healthy volunteers welcome
- Sponsor
- TruCare Internal Medicine & Infectious Disease
Hepatitis B, Chronic, Adults
Molecular Epidemiology of Hepatitis B in Cayenne General Hospital, French Guiana
In South America, the prevalence of HBV is variable but high (> 8%) in the Amazon basin. In some areas, a third of HBsAg carriers are also infected with HDV, a major comorbidity factor.
- Trial name
- NCT04886102
- Testing
- An additional 5 mL venous blood tube taken from patients during their routine medical check-up at the hospital
- Where
- French Guiana
- Volunteers
- 400 people
- Sponsor
- Centre Hospitalier de Cayenne
Chronic Hepatitis C, Renal Impairment
The Pharmacokinetics of Grazoprevir (MK-5172) and Elbasvir (MK-8742) in Participants With Renal Insufficiency (MK-5172-050)
Grazoprevir (MK-5172) and Elbasvir (MK-8742) were studied as the principal components of combination oral therapy for hepatitis C virus (HCV).
- Trial name
- NCT01937975
- Testing
- Grazoprevir, Elbasvir
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
HCV
Efficacy and Safety of Ravidasvir in Combination With Danoprevir/r and Ribavirin(RBV) in Treatment-naive, Non-cirrhotic, Chronic Hepatitis C Virus Genotype1 Infected Subjects.
The purpose of this study is to assess the efficacy and safety of Ravidasvir in combination with Danoprevir/r and ribavirin(RBV) by sustain virologic response 12 (SVR12), in treatment-naive, non-cirrhotic, chronic hepatitis C…
- Trial name
- NCT03362814
- Testing
- Ravidasvir, Danoprevir, Ritonavir
- Where
- China
- Volunteers
- 425 people
- Sponsor
- Ascletis Pharmaceuticals Co., Ltd.
Hepatitis C
HCV-TARGET- Hepatitis C Therapeutic Registry and Research Network
The primary purpose of the HCV-TARGET study is to establish a nationwide registry of patients undergoing treatment with antiviral therapies for chronic hepatitis C (HCV) at both academic and community practices.
- Trial name
- NCT01474811
- Where
- 60 sites in United States, Canada and 2 more
- Volunteers
- 13,559 people
- Sponsor
- University of North Carolina, Chapel Hill
Healthy
Study in Healthy Volunteers to Evaluate a Human Monoclonal Antibody Against Hepatitis C
This is a phase I, open-label, dose escalation study to evaluate the safety of MBL-HCV1 in healthy adult volunteers. Eligible volunteers will be admitted to a phase 1 unit for study infusion.
- Trial name
- MBL-HCV1 (NCT00952263)
- Testing
- MBL-HCV1
- Where
- United States
- Volunteers
- 31 people, healthy volunteers welcome
- Sponsor
- MassBiologics
Hepatitis C, Chronic
Evaluation of Dried Blood Spot for HCV RNA Testing
FIND is preparing a study to evaluate the performance, as measured by sensitivity and specificity, of four centralized assays for the detection of HCV RNA using capillary blood collected on dried blood spots (DBS) and plasma…
- Trial name
- NCT03896087
- Testing
- Abbott RealTime HCV assay from DBS, HCV for use on the cobas® 6800/8800 Systems from PSC and DBS, Aptima® HCV Quant Dx Assay from DBS
- Where
- 5 sites in Australia, Cameroon and 3 more
- Volunteers
- 942 people
- Sponsor
- Foundation for Innovative New Diagnostics, Switzerland
Hepatitis B, Hepatitis C
Long-Term Study of Liver Disease in People With Hepatitis B and/or Hepatitis C With or Without HIV Infection
Background: Hepatitis B and hepatitis C can cause liver damage. They can also cause serious illness, including liver cancer, and even death. This study will follow people who have hepatitis B or hepatitis C.
- Conditions
- Hepatitis B, Hepatitis C, HIV-HCV Co-Infection
- Trial name
- NCT01350648
- Where
- 2 sites in United States
- Volunteers
- 569 people
- Sponsor
- National Institutes of Health Clinical Center (CC)
Chronic Hepatitis C Infection
Evaluation of Neurocognitive Performance in Drug Substituted Patients Under Hepatitis C Therapy
Prospective, longitudinal multi-center study performed in 15 participating substitution centers in Germany. Aims: Primary objective: To compare the impact of the different substitution drugs (methadone, buprenorphine, and…
- Trial name
- NCT00682591
- Where
- Germany
- Volunteers
- 190 people
- Sponsor
- University of Wuerzburg
Hepatitis C, Chronic
Eight Weeks of Elbasvir/Grazoprevir in the Treatment of HCV Genotype 4
To evaluate the safety and efficacy of a daily, fixed-dose, 8-week course combination of Elbasvir/Grazoprevir in treatment-naïve, non-cirrhotic patients who are mono-infected with hepatitis C, genotype 4.
- Trial name
- ELEGANT-4 (NCT03578640)
- Testing
- Elbasvir, Grazoprevir 50-100Mg Oral Tablet
- Where
- Saudi Arabia
- Volunteers
- 30 people
- Sponsor
- King Fahad Medical City
Hepatitis C
A Study of Chronic Hepatitis C Patients Treated With SOF/VEL/VOX
This is a retrospective, non-interventional study. Investigators from infectious diseases and gastroenterology departments will participate this study. Patients data will be collected from hospital medical records.
- Trial name
- VOSEVI_Reg (NCT06010524)
- Where
- Turkey (Türkiye)
- Volunteers
- 450 people
- Sponsor
- Cerrahpasa Medical Faculty Foundation
Hepatitis C
Pegintron Induction Therapy in HCV Non-Responders
The purpose of this study is to compare the sustained virological response rate at 24 weeks after the end of experimental treatment (induction and 72 weeks) to that of standard 48 weeks treatment with PEG-inteferon alfa-2b and…
- Trial name
- NCT00363259
- Testing
- Peginterferon alfa-2b, Ribavirin
- Where
- 7 sites in Netherlands
- Volunteers
- 110 people
- Sponsor
- Foundation for Liver Research